Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LX2343
Cat. No.:
OB0225LY-0394
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
LX2343 is a novel small molecule inhibitor and is mainly investigated for its role in cell cycle regulation.
Synonym:
333745-53-2; LX-2343; N-(Benzo[d][1,3]dioxol-5-yl)-2-(N-(5-chloro-2-methoxyphenyl)phenylsulfonamido)acetamide; 2-[N-(Benzenesulfonyl)-5-chloro-2-methoxyanilino]-N-(1,3-benzodioxol-5-yl)acetamide; N-(1,3-Benzodioxol-5-yl)-2-[5-chloro-2-methoxy(phenylsulfonyl)anilino]acetamide
CAS No.:
333745-53-2
Compound CID:
1000980
Formula:
C22H19ClN2O6S
Formula Weight:
474.91
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LX2343 can be used in cell biology research, especially in the exploration of mechanisms regulating cell proliferation and growth.
Library Information
Targets:
Enzymes; Pathogenic proteins/peptides
Receptors:
Amyloid-β; BACE1; Beta-secretase; PI3K
Pathways:
Autophagy; Neuronal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-6
Plate Location:
a9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
55 mg/mL; 115.81 mM
